Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00115024 · ClinicalTrials.gov registry record · Phase 2

EPAT: Estrogen in the Prevention of Atherosclerosis Trial

A Phase 2 study, sponsored by National Institute on Aging (NIA).

Completed
Registry status
Phase 2
Development phase
222
Enrollment target

NCT00115024: Completed Phase 2 study, sponsored by National Institute on Aging (NIA).

NCT00115024 is a Phase 2 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 222 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00115024, a Phase 2 study, has completed, sponsored by National Institute on Aging (NIA).

COMPLETED
Registry status
Phase 2
Development phase
222 participants
Enrollment target

Study Summary

The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).

Interventions

  • DRUG Micronized 17B-estradiol

Trial Details

FieldValue
Enrollment Target 222 participants
Start Date 1994-04
Est. Completion 1998-11
Phase Phase 2
National Institute on Aging (NIA)

131 total trials

What the finished NCT00115024 record still lists

NCT00115024 is an interventional study that assigns participants to a tested intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% higher).

The record links to 0 conditions, and to 1 intervention - of which Micronized 17B-estradiol is the first listed.

NCT00115024 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00115024 about?

NCT00115024 is a clinical study titled "EPAT: Estrogen in the Prevention of Atherosclerosis Trial". The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).

What is the current status of trial NCT00115024?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 1994-04. Estimated completion is 1998-11.

What interventions are being tested in trial NCT00115024?

The interventions under investigation include: Micronized 17B-estradiol (DRUG).

Who is sponsoring clinical trial NCT00115024?

This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00115024's enrollment target sits among peer trials

222 274th of 2000 higher than 1,726 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04939610 · 222 participants · Phase 1

    A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

  • NCT05424783 · 222 participants

    MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

  • NCT05568264 · 222 participants · NA

    Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

  • NCT05605574 · 222 participants · NA

    Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00115024, the US trial registry maintained by the National Library of Medicine. NCT00115024 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.